Published in J Pharmacol Exp Ther on September 01, 1996
Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol (2001) 1.53
A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol (2000) 1.21
The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem (2009) 1.03
Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. BMC Infect Dis (2012) 0.82
Adenosine and blood platelets. Purinergic Signal (2011) 0.79
Adenosine and ischemic preconditioning. Curr Pharm Des (1999) 0.77
Pyrazolo derivatives as potent adenosine receptor antagonists: an overview on the structure-activity relationships. Int J Med Chem (2011) 0.75
A2A-adenosine receptor reserve for coronary vasodilation. Circulation (1998) 1.55
Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci (2000) 1.47
The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther (1998) 1.40
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.37
The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther (1996) 1.30
A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol (2000) 1.21
B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant (1993) 1.12
Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport (1998) 1.08
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists. J Med Chem (1996) 1.02
Antibacterial and allelopathic activity of extract from Castanea sativa leaves. Fitoterapia (2000) 0.99
Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice. Br J Pharmacol (2007) 0.98
Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br J Pharmacol (1994) 0.96
Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience (1997) 0.96
Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes. Circ Res (1996) 0.94
Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.94
2-Alkynyl derivatives of adenosine-5'-N-ethyluronamide: selective A2 adenosine receptor agonists with potent inhibitory activity on platelet aggregation. J Med Chem (1994) 0.93
The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.91
Cavernous haemangioma of the external auditory canal: clinical case and review of the literature. Acta Otorhinolaryngol Ital (2012) 0.91
Comparative ototoxicity of amikacin, gentamicin, netilmicin, and tobramycin in guinea pigs. Toxicol Appl Pharmacol (1982) 0.91
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists. J Med Chem (1998) 0.91
Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation (1999) 0.91
Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br J Pharmacol (1999) 0.91
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol (1997) 0.91
Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. Circulation (2000) 0.90
Cardiovascular pharmacology of the A2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther (1998) 0.90
[3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes. Br J Pharmacol (1998) 0.90
Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients. Dement Geriatr Cogn Disord (2012) 0.89
Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: tolerance develops to A1-mediated hemodynamic effects. J Pharmacol Exp Ther (1994) 0.89
Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol (2001) 0.89
Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig. Chemotherapy (1990) 0.89
[3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem (1998) 0.89
Effects of selective A1 and A2 adenosine receptor agonists on cardiovascular tissues. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.88
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol (1997) 0.88
Intracanalicular meningiomas. Otolaryngol Head Neck Surg (2000) 0.88
Comparison of neuromuscular effects and acute toxicity of some aminoglycoside antibiotics. Arch Int Pharmacodyn Ther (1978) 0.87
A topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model. Br J Ophthalmol (2006) 0.86
Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol (1996) 0.86
The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol (2009) 0.86
Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc Natl Acad Sci U S A (2000) 0.84
The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. Eur J Pharmacol (1993) 0.84
Comparative actions of four aminoglycoside antibiotics on the vestibular function in guinea-pigs. Arch Int Pharmacodyn Ther (1986) 0.84
Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol (1995) 0.84
Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneimittelforschung (1994) 0.83
A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs. Exp Eye Res (2011) 0.83
A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost (2005) 0.83
L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis (2000) 0.83
The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res (2001) 0.83
Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther (1996) 0.83
Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390. Eur J Pharmacol (1985) 0.83
Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists. J Cardiovasc Pharmacol (1997) 0.82
Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells. Br J Pharmacol (2011) 0.82
The Mongolian gerbil in experimental epilepsy. Ital J Neurol Sci (1995) 0.82
Absence of [3H]SCH 23390 specific binding sites in anterior pituitary: dissociation from effects on prolactin secretion. Eur J Pharmacol (1987) 0.82
Vestibulo-ocular reflex (VOR) in guinea pigs. Impairment induced by aminoglycoside antibiotics. Acta Otolaryngol (1986) 0.82
Beta 1 and beta 2 adrenoceptors are involved in mediating vasodilation in the human coronary artery. Pharmacol Res (1993) 0.81
HLA DR4 and B27 antigens in familial and sporadic rheumatoid arthritis. Scand J Rheumatol (1987) 0.81
Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding. Br J Pharmacol (1997) 0.81
Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab (1998) 0.81
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. J Med Chem (1996) 0.81
Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain. Eur J Pharmacol (1996) 0.81
Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol (2009) 0.81
Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J Pharmacol Exp Ther (1993) 0.81
Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology (2000) 0.80
Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survival. Antimicrob Agents Chemother (2003) 0.80
Binding characteristics of the adenosine A2 receptor ligand [3H]CGS 21680 to human platelet membranes. Biochem Pharmacol (1994) 0.80
Recovery of mononuclear cell subsets after bone marrow transplantation: overabundance of CD4+CD8+ dual-positive T cells reminiscent of ontogeny. J Hematother (1992) 0.80
Differences between binge eating disorder and nonpurging bulimia nervosa. Int J Eat Disord (1999) 0.80
Stimulation of dopamine D-1 receptors by SKF 38393 induces EEG desynchronization and behavioral arousal. Life Sci (1985) 0.80
In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur J Neurosci (2001) 0.80
2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity. J Med Chem (1995) 0.79
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists. J Med Chem (1995) 0.79
The dopamine D1 receptor is involved in the regulation of REM sleep in the rat. Eur J Pharmacol (1991) 0.79
Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. Hypertension (1995) 0.79
The sedative-hypnotic properties of quazepam, a new hypnotic agent. Arzneimittelforschung (1982) 0.79
Telemetry monitoring of hemodynamic effects induced over time by adenosine agonists in spontaneously hypertensive rats. J Pharmacol Exp Ther (1995) 0.78
Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig. Chemotherapy (1990) 0.78
Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats. J Hypertens Suppl (1991) 0.78
Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1993) 0.78
Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol (1994) 0.78
Frontal sinus osteoma and palpebral abscess: case report. Rev Laryngol Otol Rhinol (Bord) (2005) 0.78
The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol (1992) 0.78
Intrinsic and antagonistic effects of beta-carboline FG 7142 on behavioral and EEG actions of benzodiazepines and pentobarbital in cats. Eur J Pharmacol (1983) 0.78
[Tension-free hernioplasty in the treatment of inguinal hernia in the adult: our experience with local anesthesia and a review of the literature]. Minerva Chir (1999) 0.78
SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine. Eur J Pharmacol (1985) 0.77
Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat. Eur J Pharmacol (1985) 0.77
[3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur J Pharmacol (1985) 0.77
Cardioprotective effects of adenosine A1 and A2A receptor agonists in the isolated rat heart. Pharmacol Res (1997) 0.77
Preferential affinity of 3H-2-oxo-quazepam for type I benzodiazepine recognition sites in the human brain. Life Sci (1988) 0.77
6-Hydroxydopamine-induced degeneration of nigral dopamine neurons: differential effect on nigral and striatal D-1 dopamine receptors. Life Sci (1987) 0.77
Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5'-N-ethylcarboxamidoadenosine. Arzneimittelforschung (1994) 0.77